AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$CLYM

Thomas Stephen Basil sold $1.4M of CLYM

Thomas Stephen Basil sold 100,000 shares of Climb Bio, Inc. (CLYM) at $13.67 ($1.37M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomas Stephen Basil
Published Sep 17, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CLYM
Bearish
medium confidence
Mentioned
$CLYM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLYMBearishLow
01

Why it matters

The director's sale may be interpreted by the market as a bearish cue, but the modest size limits impact.

02

Market read

Insider sale provides fresh data for traders monitoring Climb Bio; likely modest price effect.

03

What to watch

Potential upcoming clinical data releases or financing events that could offset the sell signal.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑09‑15

Background

SEC Form 4 filing discloses insider transactions; required to be reported within two business days.

Company-level read

Ticker impact

$CLYMBearishMedium confidence
Context

Director Thomas Stephen Basil sold 100,000 shares of Climb Bio for $1.37M via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

potential short‑term downside pressure

Evidence & confidence

The sale size ($1.4M) is modest but the insider is a director; market may interpret as a negative signal.

Market effects

Sector

Limited impact; biotech sector may see slight sentiment drag from insider sell.

Regional

Minimal, primarily affects US biotech investors.

Global

Low, confined to Climb Bio shareholders.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect any negative outlook.

Key entities

  • Company
    Climb Bio, Inc.

    Biotech firm developing therapies for rare diseases.

  • Individual
    Thomas Stephen Basil

    Director of Climb Bio who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLYM insider trading history →

Related articles

OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

SEC EDGAR 8-K2 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

markets.businessinsider.com3 min
OCT 20
$CLYMHigh

Why is Climb Bio stock surging today?

Climb Bio Inc. (CLYM) rose 10.9% after Deutsche Bank initiated coverage with a Buy rating and $28.00 target, citing its autoimmune drug pipeline. The bank noted recent valuation compression reflected sector-wide selloff, not company-specific issues. Multiple analysts maintain bullish ratings with targets up to $40, citing positive clinical data. Broader market gains and biotech sector stabilization also supported the move.

investing.com2 min
OCT 20
$CLYMHigh

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.

investing.com2 min